A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...
Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.
Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...
Zacks.com on MSN2d
Study: Merck and Daiichi's Lung Cancer Treatment Shows PromiseMerck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...
Gefapixant decreased cough-induced stress urinary incontinence (CSUI) episodes in women with refractory/unexplained chronic cough and CSUI.
Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical company Merck.
BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback